BORA-dependent PLK1 regulation: A new weapon for cancer therapy?

Mol Cell Oncol. 2016 Jun 27;3(5):e1199265. doi: 10.1080/23723556.2016.1199265. eCollection 2016.

Abstract

The mitotic kinase polo like kinase 1 (PLK1) is overexpressed in many cancers and its inhibition slows down proliferation and increases apoptosis in cancer cell lines. Understanding how PLK1 is activated is therefore crucial for the development of novel PLK1 inhibitors with anticancer properties. We recently identified a conserved regulatory loop leading to PLK1 activation that involves cyclin-dependent kinase 1 (CDK1).

Keywords: CDK1; Cell cycle; DNA damage; PLK1; cell division.